Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Brief Summary: This is a randomized phase II study, aimed at evaluating the efficacy (through progression free survival at 6 months) and safety of 5 different treatments involving atezolizumab, bevacizumab and/or acetylsalicylic acid in advanced recurrent platinum-resistant ovarian cancer patients in order to select the optimal treatments for further development in Phase III.


Options:
A: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: atezolizumab + bevacizumab + placebo; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: atezolizumab, Drug: placebo | Arm Label: atezolizumab + bevacizumab + acetylsalicylic acid; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: atezolizumab, Drug: acetylsalicylic acid | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab, atezolizumab + bevacizumab + acetylsalicylic acid, atezolizumab + bevacizumab + placebo | Intervention Type: DRUG; Name: atezolizumab; Assigned to Arm(s): atezolizumab + bevacizumab + acetylsalicylic acid, atezolizumab + bevacizumab + placebo | Intervention Type: DRUG; Name: acetylsalicylic acid; Assigned to Arm(s): atezolizumab + bevacizumab + acetylsalicylic acid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): atezolizumab + bevacizumab + placebo
B: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab
C: Arm Label: Pembrolizumab + paclitaxel ± bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Docetaxel | Arm Label: Placebo + paclitaxel ± bevacizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Other: Placebo for pembrolizumab, Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab | Intervention Type: OTHER; Name: Placebo for pembrolizumab; Assigned to Arm(s): Placebo + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Arm B, Arm C | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm B, Arm C

Answer: A